Feed ICCC
Summary
50 / 100 · Bulios Score
Valuation 31Growth 67Profitability 61Quality 32Debt 80Stability 32
What speaks for it
- Revenue grew by 14% a year over the last 3 years.
- Out of every 100 USD of revenue, 14 USD is left as free cash.
What to watch
- Out of every 100 USD of revenue, only 2.6 USD is left as net profit.
- Operating profit covers the interest on its debt only 2.7 times.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveP/E today 120.4
Biotechnology industry median
Today you pay 120.4 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
2021202220232024202520262027
Diluted EPS (USD)
2021202220232024202520262027
- Analyst estimate
Revenue grew by 12% a year over 5 years. Over the last 3 years it grew by 14% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 60 USD
- Research and development 6.2 USD
- Sales and administration 22 USD
- Taxes and other 10 USD
- Net profit 2.6 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 2.6 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $8.86M
Debt $12.4M
Free cash flow over 12 months $4.21M
Repaying all its debt would take 3.0 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2021By product
- FirstDefenseProductLineMember 98%
- OtherAnimalHealthMember 1.6%
By region
- UNITED STATES 100%
FirstDefenseProductLineMember brings in 98% of revenue.
Segments in detail